INR 117.54
(-1.34%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 148.62 Million INR | 9.35% |
2022 | 135.91 Million INR | 14.32% |
2021 | 118.89 Million INR | -41.75% |
2020 | 204.12 Million INR | -47.1% |
2019 | 385.84 Million INR | -81.44% |
2018 | 2.07 Billion INR | 42.28% |
2017 | 1.46 Billion INR | -1.74% |
2016 | 1.48 Billion INR | -21.8% |
2015 | 1.9 Billion INR | -11.06% |
2014 | 2.13 Billion INR | -3.76% |
2013 | 2.22 Billion INR | 23.66% |
2012 | 1.79 Billion INR | 14.1% |
2011 | 1.57 Billion INR | 62.51% |
2010 | 968.96 Million INR | 11.77% |
2009 | 866.88 Million INR | 20.9% |
2008 | 717.01 Million INR | -22.18% |
2007 | 921.43 Million INR | 28.47% |
2006 | 717.22 Million INR | 35.8% |
2005 | 528.14 Million INR | -3.25% |
2004 | 545.88 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 192.8 Million INR | 107.14% |
2024 Q1 | -2.7 Billion INR | -1916.97% |
2023 FY | 148.62 Million INR | 9.35% |
2023 Q1 | - INR | -100.0% |
2023 Q4 | 148.62 Million INR | 0.0% |
2023 Q2 | 118.28 Million INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2022 Q2 | 641.07 Million INR | 0.0% |
2022 Q4 | 135.91 Million INR | 0.0% |
2022 FY | 135.91 Million INR | 14.32% |
2022 Q1 | - INR | -100.0% |
2022 Q3 | - INR | -100.0% |
2021 Q2 | 128.46 Million INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 FY | 118.89 Million INR | -41.75% |
2021 Q4 | 118.89 Million INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2020 Q1 | - INR | -100.0% |
2020 FY | 204.12 Million INR | -47.1% |
2020 Q2 | 250.19 Million INR | 0.0% |
2020 Q4 | 204.12 Million INR | 0.0% |
2019 FY | 385.84 Million INR | -81.44% |
2019 Q4 | 385.84 Million INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 Q3 | - INR | -100.0% |
2019 Q2 | 3.14 Billion INR | 0.0% |
2018 Q4 | 2.07 Billion INR | 0.0% |
2018 Q1 | - INR | 0.0% |
2018 FY | 2.07 Billion INR | 42.28% |
2017 FY | 1.46 Billion INR | -1.74% |
2016 FY | 1.48 Billion INR | -21.8% |
2016 Q4 | 1.48 Billion INR | 0.0% |
2015 FY | 1.9 Billion INR | -11.06% |
2015 Q1 | - INR | -100.0% |
2015 Q2 | 2.08 Billion INR | 0.0% |
2015 Q3 | - INR | -100.0% |
2015 Q4 | 1.9 Billion INR | 0.0% |
2014 Q3 | - INR | -100.0% |
2014 Q1 | - INR | -100.0% |
2014 Q2 | 1.86 Billion INR | 0.0% |
2014 FY | 2.13 Billion INR | -3.76% |
2014 Q4 | 2.13 Billion INR | 0.0% |
2013 Q4 | 2.22 Billion INR | 0.0% |
2013 FY | 2.22 Billion INR | 23.66% |
2013 Q2 | 2.18 Billion INR | 0.0% |
2013 Q3 | - INR | -100.0% |
2013 Q1 | - INR | -100.0% |
2012 Q2 | 3.52 Billion INR | 0.0% |
2012 Q3 | - INR | -100.0% |
2012 Q4 | 1.79 Billion INR | 0.0% |
2012 FY | 1.79 Billion INR | 14.1% |
2011 FY | 1.57 Billion INR | 62.51% |
2010 FY | 968.96 Million INR | 11.77% |
2009 FY | 866.88 Million INR | 20.9% |
2008 FY | 717.01 Million INR | -22.18% |
2007 FY | 921.43 Million INR | 28.47% |
2006 FY | 717.22 Million INR | 35.8% |
2005 FY | 528.14 Million INR | -3.25% |
2004 FY | 545.88 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 91.37% |
Aarti Drugs Limited | 11.5 Billion INR | 98.708% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 98.199% |
Ajanta Pharma Limited | 10.71 Billion INR | 98.612% |
Alembic Limited | 1.43 Billion INR | 89.622% |
Alkem Laboratories Limited | 48.6 Billion INR | 99.694% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 99.087% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 95.941% |
Bal Pharma Limited | 2.51 Billion INR | 94.082% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | 48.538% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 92.953% |
Brooks Laboratories Limited | 248.6 Million INR | 40.217% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | 77.215% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 95.76% |
Divi's Laboratories Limited | 18.99 Billion INR | 99.217% |
Eris Lifesciences Limited | 38.26 Billion INR | 99.612% |
Granules India Limited | 22.95 Billion INR | 99.353% |
Ind-Swift Limited | 13.45 Billion INR | 98.895% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | 49.919% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 98.612% |
Jubilant Pharmova Limited | 61.27 Billion INR | 99.757% |
Kilitch Drugs (India) Limited | 643.88 Million INR | 76.918% |
Medicamen Biotech Limited | 940.36 Million INR | 84.195% |
Medico Remedies Limited | 438.24 Million INR | 66.087% |
Wockhardt Limited | 39.87 Billion INR | 99.627% |
Orchid Pharma Limited | 3.84 Billion INR | 96.134% |
RPG Life Sciences Limited | 1.38 Billion INR | 89.232% |
Shilpa Medicare Limited | 12.93 Billion INR | 98.851% |
Sigachi Industries Limited | 2.53 Billion INR | 94.129% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 98.945% |
Unichem Laboratories Limited | 8.06 Billion INR | 98.158% |
Vaishali Pharma Limited | 371.16 Million INR | 59.958% |
Wanbury Limited | 3.15 Billion INR | 95.29% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.793% |
FDC Limited | 3.7 Billion INR | 95.993% |
Amrutanjan Health Care Limited | 783.82 Million INR | 81.039% |
Bajaj HealthCare Limited | 4.86 Billion INR | 96.947% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.861% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 97.131% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 93.508% |
Laurus Labs Limited | 42.71 Billion INR | 99.652% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 92.48% |
Nectar Lifesciences Limited | 11.21 Billion INR | 98.675% |
Par Drugs and Chemicals Limited | 159.79 Million INR | 6.99% |
Hester Biosciences Limited | 3.59 Billion INR | 95.866% |
Ipca Laboratories Limited | 33.74 Billion INR | 99.56% |
Venus Remedies Limited | 1.39 Billion INR | 89.329% |
ZIM Laboratories Limited | 2.08 Billion INR | 92.857% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.902% |
Morepen Laboratories Limited | 4.45 Billion INR | 96.668% |
Neuland Laboratories Limited | 5.49 Billion INR | 97.297% |
Sequent Scientific Limited | 8.27 Billion INR | 98.204% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 92.694% |
Valiant Laboratories Limited | 1.05 Billion INR | 85.956% |
Windlas Biotech Limited | 1.76 Billion INR | 91.569% |
Hikal Limited | 12.99 Billion INR | 98.856% |
Innova Captab Limited | 4.89 Billion INR | 96.967% |
Procter & Gamble Health Limited | 2.56 Billion INR | 94.197% |
Themis Medicare Limited | 1.88 Billion INR | 92.126% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 97.652% |
Mankind Pharma Limited | 23.87 Billion INR | 99.377% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.772% |
Sakar Healthcare Limited | 1.26 Billion INR | 88.235% |
Albert David Limited | 1.15 Billion INR | 87.078% |
Lupin Limited | 96.23 Billion INR | 99.846% |
Gufic Biosciences Limited | 5.59 Billion INR | 97.346% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.919% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 86.169% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 87.245% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.973% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.819% |
NATCO Pharma Limited | 10.53 Billion INR | 98.589% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 95.003% |
Strides Pharma Science Limited | 37.68 Billion INR | 99.606% |
Indoco Remedies Limited | 10.34 Billion INR | 98.563% |
Alpa Laboratories Limited | 307.12 Million INR | 51.608% |
Lasa Supergenerics Limited | 541.92 Million INR | 72.575% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 96.182% |